In this study the effect of liquisolid technique on the dissolution profile of spironolactone was evaluated. Different formulations of spironolactone liquisolid compacts were prepared using various amounts of non-volatile vehicles (Poly ethylene glycol 400 and glycerin). The ratio of microcrystalline cellulose (as carrier) to silica (as coating powder material) was 20 for all formulations. Afte...

Spironolactone has produced beneficial effects in animal models of neurodegenerative disorders. However, the underlying mechanisms of this agent on neurons and glia are mostly unknown. Therefore, we aimed to show the effects of spironolactone and fludrocortisone, a mineralocorticosteroid receptor agonist, on neuronal and glial toxicity induced by N-methyl-D-aspartate (NMDA) activation and chlor...

In eight patients with cirrhosis and stable ascites controlled on chlorothiazide and spironolactone, a small particle preparation of spironolactone (Aldactone A) was as effective, at one quarter the dosage, as conventional spironolactone (Aldactone). Plasma spironolactone metabolite levels and urinary excretion of spironolactone metabolite were equivalent with both preparations. The variable do...

OBJECTIVES Ascertain alterations in volume-weighted glomerular volume in monotherapy of spontaneously hypertensive rats with different doses of spironolactone. MATERIAL AND METHODS We have studied young adult male spontaneously hypertensive rats (SHR) 20 weeks old, divided in 4 groups of 5 animals each: Controls, spironolactone lower dose (5mg/kg/day), spironolactone average dose (10mg/kg/day...

BACKGROUND Crohn's disease causes intestinal inflammation leading to intestinal fibrosis. Spironolactone is an antifibrotic medication commonly used in heart failure to reduce mortality. We examined whether spironolactone is antifibrotic in the context of intestinal inflammation. METHODS In vitro, spironolactone repressed fibrogenesis in transforming growth factor beta (TGF-β)-stimulated huma...

Cardiovascular disease causes significant morbidity and mortality among patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Several small clinical trials have shown the beneficial effects of spironolactone therapy on cardiac function in CKD patients. However, the effect of spironolactone on cardiovascular outcomes in CKD and ESRD patients is not clear. The objective o...

Spironolactone is recommended as fourth-line therapy for essential hypertension despite few supporting data for this indication. We evaluated the effect among 1411 participants in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm who received spironolactone mainly as a fourth-line antihypertensive agent for uncontrolled blood pressure and who had valid BP measurements be...

Objectives: To examine whether the favourable effects on endothelial function, vascular angiotensin converting enzyme (ACE) activity, cardiac remodelling, autonomic function, and QT intervals of spironolactone in combination with ACE inhibitor also occur in patients with New York Heart Association class I–II congestive heart failure (CHF) taking optimal treatment (including b blockers). Methods...

BACKGROUND Spironolactone is often used to treat hypertension caused by hyperaldosteronism, and as a result, can form concentrically laminated electron dense spironolactone body inclusions within the adrenal gland. Spironolactone bodies have not been investigated in a contemporary cohort or in patients treated with the more recently approved aldosterone antagonist, eplerenone. METHODS Spirono...

AIMS Spironolactone is widely used to treat heart failure, hypertension and liver disease with increased usage in recent years. Spironolactone has endocrine effects that could influence cancer risks and historical reports suggest possible links with increased risk of certain types of cancer. The aim of this study was to assess the effect of spironolactone exposure on cancer incidence. METHODS...